 |
|
NIAID DNA vaccine for H5N1 avian influenza enters human trial
January 05, 2007The first human trial of a DNA vaccine designed to prevent H5N1 avian influenza infection began on December 21, 2006, when the vaccine was administered to the first volunteer at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. Scientists from the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), one of the NIH Institutes, designed the vaccine. The vaccine does not contain any infectious material from the influenza virus.
Unlike conventional flu vaccines, which are developed by growing the influenza virus in hens' eggs and then administered as a weakened or killed form of the virus, DNA-based vaccines contain only portions of the influenza virus' genetic material. Once inside the body, the DNA instructs human cells to make proteins that act as a vaccine against the virus.
VRC Director Gary Nabel, M.D., Ph.D., together with a team of scientists from the VRC recognized the potential for employing new vaccine technology against influenza, a disease for which effective vaccines have long been made, but for which the reliability of supply and manufacturing capacity has been problematic. Dr. Nabel and his colleagues previously have shown the DNA vaccine approach to be effective against influenza viruses in animal models, including highly pathogenic viruses such as the H5N1 strain and the H1N1 virus that caused the deadly 1918 pandemic. The DNA vaccine used in this study is similar to other investigational vaccines evaluated by the VRC that hold promise for controlling other viruses, such as HIV, Ebola, SARS and West Nile.
"An effective H5N1 influenza vaccine would provide a potentially life-saving advance against a global health threat," notes NIAID Director Anthony S. Fauci, M.D. "More broadly, development of this DNA vaccine technology has the potential to improve our production capacity for vaccines to prevent seasonal influenza and other diseases."
"This influenza vaccine trial is further evidence of the ability of the NIAID Vaccine Research Center to rapidly translate basic research into potential products," he adds. "Our accelerated effort to understand and find new solutions to pandemic influenza is part of the NIAID commitment to respond to new emerging infectious disease threats and to improve public health preparedness."
Highly pathogenic avian influenza A viruses, specifically H5N1, have emerged in the past decade, causing widespread sickness and death in domestic and wild bird populations. As of December 27, 2006, 261 laboratory-confirmed human cases of H5N1 had been reported to the World Health Organization, resulting in death of more than half of infected individuals. While human cases remain relatively rare and are largely the result of direct virus transmission from infected birds, a few cases of human-to-human transmission have been reported. The severity of disease and the potential for human-to-human spread has provided a major incentive to accelerate developing a human vaccine for avian influenza.
With the spread of avian influenza virus, new strains have emerged, including clade II viruses in Indonesia and elsewhere that have drifted genetically from the initial strains detected in Southeast Asia. With this study, the investigators hope to learn whether new technologies, such as DNA vaccines, can provide protection against such viruses.
"This vaccine is aimed at newer strains of the H5N1 virus that currently pose a threat in Indonesia and represents an example of our ability to respond to shifting viruses with modern technology," says Dr. Nabel.
The study will enroll 45 volunteers between the ages of 18 and 60. Fifteen will receive placebo injections and 30 will receive three injections of the investigational vaccine over 2 months and will be followed for 1 year. Volunteers will not be exposed to influenza virus.
The vaccine contains no infectious material, and the virus was not present during any stage of the manufacturing process, notes Julie E. Martin, D.O., principal investigator of the study. "It is impossible for the vaccine to cause infection," she adds, "because it employs new technology known to safely stimulate broad immune responses." NIAID researchers will measure immune responses to the vaccine, assess its safety, and compare its potency to more traditional vaccine approaches.
NIH/National Institute of Allergy and Infectious Diseases
"An effective H5N1 influenza vaccine would provide a potentially life-saving advance against a global health threat," notes NIAID Director Anthony S. Fauci, M.D. "More broadly, development of this DNA vaccine technology has the potential to improve our production capacity for vaccines to prevent seasonal influenza and other diseases."
"This influenza vaccine trial is further evidence of the ability of the NIAID Vaccine Research Center to rapidly translate basic research into potential products," he adds. "Our accelerated effort to understand and find new solutions to pandemic influenza is part of the NIAID commitment to respond to new emerging infectious disease threats and to improve public health preparedness."
Highly pathogenic avian influenza A viruses, specifically H5N1, have emerged in the past decade, causing widespread sickness and death in domestic and wild bird populations. As of December 27, 2006, 261 laboratory-confirmed human cases of H5N1 had been reported to the World Health Organization, resulting in death of more than half of infected individuals. While human cases remain relatively rare and are largely the result of direct virus transmission from infected birds, a few cases of human-to-human transmission have been reported. The severity of disease and the potential for human-to-human spread has provided a major incentive to accelerate developing a human vaccine for avian influenza.
With the spread of avian influenza virus, new strains have emerged, including clade II viruses in Indonesia and elsewhere that have drifted genetically from the initial strains detected in Southeast Asia. With this study, the investigators hope to learn whether new technologies, such as DNA vaccines, can provide protection against such viruses.
"This vaccine is aimed at newer strains of the H5N1 virus that currently pose a threat in Indonesia and represents an example of our ability to respond to shifting viruses with modern technology," says Dr. Nabel.
The study will enroll 45 volunteers between the ages of 18 and 60. Fifteen will receive placebo injections and 30 will receive three injections of the investigational vaccine over 2 months and will be followed for 1 year. Volunteers will not be exposed to influenza virus.
The vaccine contains no infectious material, and the virus was not present during any stage of the manufacturing process, notes Julie E. Martin, D.O., principal investigator of the study. "It is impossible for the vaccine to cause infection," she adds, "because it employs new technology known to safely stimulate broad immune responses." NIAID researchers will measure immune responses to the vaccine, assess its safety, and compare its potency to more traditional vaccine approaches.
NIH/National Institute of Allergy and Infectious Diseases
Avian Influenza Current Events and Avian Influenza News RSSNew research helps explain why bird flu has not caused a pandemic
Bird flu viruses would have to make at least two simultaneous genetic mutations before they could be transmitted readily from human to human, according to research published today in PLoS ONE.
Initial Results Show Pregnant Women Mount Strong Immune Response To One Dose of 2009 H1N1 Flu Vaccine
Healthy pregnant women mount a robust immune response following just one dose of 2009 H1N1 influenza vaccine, according to initial results from an ongoing clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.
Triple-Combo Drug Shows Promise Against Antiviral-Resistant Swine Flu, UAB Researcher Says
An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases.
Media source impacts ag biotech communication
Communication between the public and government is a necessary component of public trust. For many modern issues, constituents trust that their legislators understand the science behind these topics and pass legislation for the betterment of society.
Earlier flu viruses provided some immunity to current H1N1 influenza, study shows
University of California, Davis, researchers studying the 2009 H1N1 influenza virus, formerly referred to as "swine flu," have identified a group of immunologically important sites on the virus that are also present in seasonal flu viruses that have been circulating for years.
World will miss 2010 target to stem biodiversity loss, experts say
The world will miss its agreed target to stem biodiversity loss by next year, according to experts convening in Cape Town for a landmark conference devoted to biodiversity science.
IOM report released on species-jumping diseases
Significant weaknesses undermine the global community's abilities to prevent, detect early, and respond efficiently to potentially deadly species-crossing microbes, such as the pandemic H1N1 influenza virus sweeping the globe, says a new report from the Institute of Medicine and National Research Council.
Early results: In children, 2009 H1N1 influenza vaccine works like seasonal flu vaccine
Early results from a trial testing a 2009 H1N1 influenza vaccine in children look promising, according to the trial sponsor, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
H1N1 Pandemic Virus Does Not Mutate Into 'Superbug' in UMd. Lab Study
A laboratory study by University of Maryland researchers suggests that some of the worst fears about a virulent H1N1 pandemic flu season may not be realized this year, but does demonstrate the heightened communicability of the virus.
Bird flu leaves the nest -- adapting to a new host
Current research suggests that viral polymerase may provide a new therapeutic target for host-adapted avian influenza.
More Avian Influenza Current Events and Avian Influenza News Articles
 |
Avian Influenza by David E. Swayne (Editor) Avian Influenza provides the first comprehensive guide covering the full spectrum of this complex and increasingly high-profile disease, its history and its treatment and control. All aspects of avian influenza are dealt with in depth, systematically covering biology, virology, diagnostics, ecology, epidemiology, clinical medicine, and the control. The book fuses coverage of the latest discoveries in the basic sciences with a practical approach to dealing with the disease in a clinical setting, and providing instruction and guidance for veterinarians and government animal health officials encountering this disease in the field. Avian Influenza provides the reader with a global perspective, bringing together chapters written by leading animal health researchers and... |
 |
Pandemic Influenza, Swine Flu, Avian Flu Kit / Protective Apparel Emergency Disaster and First Aid Protection, Survival Transit Set with 1 Ex. Lg. Full Length Protective Coverall, 1 Face Mask with Eye Shield, 1 Pair of Lg. Gloves, 1 Pair of Lg. Shoe Covers - Safety Toggs / Frogg Toggs Brand - Polyspun Breathable Synthetic Fabric Disposable Set by Safety Toggs / Frogg Toggs Brand Product A Factory Sealed Brand New Safety Toggs / Frogg Toggs Brand Portable Home, Travel and Glovebox First Aid and Emergency Survival and Emergency Preparedness Disaster Accessory. This is a Basic Emergency Flu, Germ - Disease Emergency Disposable Apparel Kit. All Components are Extra Large, the Full Length Coverall Features a Polyspun Fabric Covered Neck to Crotch Zipper. These Components Are NOT WATERPROOF.. The Largest Test Subject we could find was 5" 11" tall, 44/46" waisted, and a shy bit under 300 lbs, they fit snugly but closed just fine, The Coverall's feature the Safety Toggs / Frogg Toggs Brand Name Logo. The Gloves fit most Lg./Ex. Large Hands, The Mask Fits Most Adults, and the Shoe Covers fit Men's Size 10 to 12. Great for Fast Evacuation and Transit, Self Rescue, and... |
 |
Avian Influenza (NCME Video 853) Also With: Network For Continuing Medical Education (Primary Contributor), Alan M. Sanders (Primary Contributor) Global concern about the potential for pandemic avian influenza is rooted in the pathogenicity of avian influenza virus strains in humans and the lack of immunity to these highly mutable viruses in the general population. Avian influenza A (H5N1) re-emerged in 2003 with greater virulence and a wider host range than that seen following its 1997 debut. Although transmission of avian influenza A (H5N1) from animals to humans remains inefficient at this time, mutation or genetic reassortment with human influenza virus strains could trigger an influenza pandemic facilitated by the mobility of modern society and the lack of an effective vaccine. Dr. Alan Sanders provides timely, practical advice on how to improve clinical awareness and implement strategies for diagnosing, treating, and... |
 |
Avian Influenza (NCME Video 853) Also With: Network for Continuing Medical Education (Primary Contributor), Alan M. Sanders (Primary Contributor) Global concern about the potential for pandemic avian influenza is rooted in the pathogenicity of avian influenza virus strains in humans and the lack of immunity to these highly mutable viruses in the general population. Avian influenza A (H5N1) re-emerged in 2003 with greater virulence and a wider host range than that seen following its 1997 debut. Although transmission of avian influenza A (H5N1) from animals to humans remains inefficient at this time, mutation or genetic reassortment with human influenza virus strains could trigger an influenza pandemic facilitated by the mobility of modern society and the lack of an effective vaccine. Dr. Alan Sanders provides timely, practical advice on how to improve clinical awareness and implement strategies for diagnosing, treating, and... |
 |
Avian Influenza ("Bird Flu") N95 Masks cs/120 masks by Cardinal |
 |
Avian Influenza H5N1 Strain Virus Chicken Fowl Photographic Poster Print, 16x12 by Art.com Art.com is the world's largest retailer of art prints, posters, photographs, and framed artwork. With our huge selection of over 400,000 prints, you'll easily find the perfect piece for your home, office, or classroom. Our art is printed on quality paper. When you order framed artwork, the piece is built by our team of in-house professionals. Visit our Amazon store today at www.amazon.com/artdotcom to find Special Offers and search for products based on 'Artist Name' and 'Subject Categories' such as Movie, Music, Vintage, TV, Children, Travel, Kitchen, Museum Art, Animals, Floral, Motivational, and Sports. Art.com is dedicated to providing you with high quality products and service by offering you 100% satisfaction guaranteed. We ship internationally to over 80 countries. Decorate your... |
 |
Avian Influenza Mountain Animal Hospital (Primary Contributor) |
 |
Gerson N95 Particulate respirator with exhale valve (10 per Box) by Gerson These Disposable Respirators Are Produced From State Of The Art Filtration Media, And Are Electro Statically Charged To Enhance Filtration And Provide Low Breathing Resistance Making The Wearer Comfortable For Extended Periods. Designed With A Double Shell Construction Makes These Respirators Collapse Resistant And Able To Withstand Hot And Humid Conditions Thereby Extending The Life And Making These A Great Value. The Built In Low Pressure Drop (lpd) Exhalation Valve Aids The Wearer With Easier Breathing Making These A Great Choice For Comfort Use., Uom 10/box |
 |
Avian Influenza Virus (Methods in Molecular Biology) by Erica Spackman (Editor) With the growing global fear of a major pandemic, avian influenza virus research has increased greatly in importance during this young century. In "Avian Influenza Virus", an expert team of researchers and diagnosticians examine the fundamental yet essential virological methods for AI virus research and diagnostics as well as some of the newest molecular procedures currently used for basic and applied research. Exciting, cutting-edge new methods focus on studying the virus itself and work with avian hosts, an area greatly lacking in research. Following the format of the highly successful "Methods in Molecular Biology" series, each chapter provides readily reproducible laboratory protocols offering step-by-step instruction and lists of the necessary equipment for the task. Comprehensive... |
 |
American Fever: A Tale of Romance & Pestilence by Peter Christian Hall An independent blog novel about a flu pandemic that strikes New York, igniting passion and disorder. This live, linked, frequently illustrated serial book will post daily into December 2009 Once fully posted, it will be available for purchase.Kindle blogs are fully downloaded onto your Kindle so you can read them even when you're not wirelessly connected. And unlike RSS readers which often only provide headlines, blogs on Kindle give you full text content and images, and are updated wirelessly throughout the day. |
| © 2009 BrightSurf.com |